Sheng Ye Capital Announces 2019 Interim Results

– Income from Factoring and Other Services Surges 30.0% to RMB237.5 Million
– Healthy Financial Position and Excellent Factoring Business Performance
– Makes Application to HKEX for Transfer of Listing to Main Board to Seize Future Opportunities

Sheng Ye Capital Limited (“Sheng Ye Capital” or the “Group”; Stock code: 8469), a specialised enterprise financial services provider offering accounts receivable financing and other related solutions mainly in the energy, construction and medical sectors in the PRC, has today announced its interim results for the six months ended 30 June 2019 (the “Review Period” or “1H 2019”).

The Group continued to record encouraging results in 1H 2019, with income from factoring and other services amounting to approximately RMB237.5 million (1H 2018: RMB182.7 million), representing an increase of approximately 30.0%. The increase was mainly attributable to an expanded factoring business that was supported by a major portion of proceeds generated from the placing exercise conducted in July 2018 as well as bank and other borrowings. The Group’s profit before taxation increased by 46.7% to approximately RMB160.2 million (1H 2018: RMB109.1 million). Profit after taxation also climbed by 67.0% to RMB124.9 million (1H 2018: RMB74.8 million). Basic earnings per share were RMB14 cents (1H 2018: RMB10 cents).

Notwithstanding the slowdown of the global and PRC economies, the Group managed to raise additional working capital for expanding the factoring operation through shares placing, borrowing and bond issuance. The Group’s revenue in 1H2019 increased by approximately 52.3% to RMB201.6 million (1H 2018: RMB132.4 million). In order to improve cash flow as well as to more effectively manage the Group’s factoring receivables portfolio and fund the factoring business, the Group sold the rights of factoring assets and recorded revenue of approximately RMB35.9 million (1H 2018: RMB50.3 million) from the sales of factoring assets, providing financing support to the factoring business. 

Business Review
Sheng Ye Capital has positioned itself as a specialised enterprise financial services provider offering accounts receivable financing and other related solutions to the energy, construction and medical sectors in the PRC. The Group has also sought to strategically expand its factoring service customer base, comprising small and medium-sized enterprises that are suppliers of state-owned enterprises and large enterprises in the abovementioned three sectors. During the Review Period, the Group provided these customers with funds secured by, among others, their accounts receivable, and also offered them accounts receivable management services, including review and verification of documents relating to the accounts receivables, collection of accounts receivable on behalf of customers, and regular reporting to customers on matters concerning their accounts receivable. The Group received interest income and professional fees for the services rendered and also derived income from the sale of rights of the factoring assets.

The Group’s online factoring platform “Easy Factoring” linked up with the enterprise credit reporting system of People’s Bank of China, following which stringent risk supervision will be conducted. This will include examining the background of co-operating enterprises, such as their operation status and credit record, and also implementing risk control on overdue situation as well as examining and verifying customers’ asset information.

Besides, SY Factoring Limited, a subsidiary of the Group, also signed a strategic co-operative agreement with a financial asset trading platform in the PRC, which will combine the strengths of the two parties, leading to resource and system integration and information sharing. 

The Group has been diversifying its financing channels and has achieved notable results. The signing of banking facility agreements with a number of banks this year has also helped the Group to implement an inclusive financial strategy that is promoted by the country.

The Group was included as one of the constituents of MSCI China All Shares Small Cap Index in 2018, demonstrating the widespread recognition that it enjoys for its financial position and business development. The Group believes the inclusion in the Index will enable it to draw greater attention from investors. On the other hand, Sheng Ye Information Technology Service (Shenzhen) Co., Limited, another subsidiary of the Group, was named “National High and New Technology Enterprise” and “Shenzhen High and New Technology Enterprise” by Shenzhen Municipal Tax Service, State Administration of Taxation, Science and Technology Innovation Committee of Shenzhen Municipality and Finance Commission of Shenzhen Municipality.

Prospects
The Group listed on GEM of Hong Kong Exchanges and Clearing Limited (“HKEX”) in 2017, making it the first and only factoring company from the PRC to list in Hong Kong. The listing status and funds raised have undoubtedly enhanced the Group’s brand image, financial position and competitive strength. On 30 April 2019, the Group made an application to HKEX for the transfer of its listing to the Main Board. It considers that the transfer of listing will help raise investors’ awareness and acceptance of the “Sheng Ye Capital” brand and enable it to gain access to more efficient financing channels both locally and abroad to support business growth. 

Looking ahead, the Group will continue to focus on the construction, energy and medical sectors and expand its clientele and factoring assets. With its advanced online factoring platform “Easy Factoring” and professional risk management mechanism, the Group will be able to offer financial products, customised solutions and also integrated factoring services including account receivable financing, account receivable management services and credit evaluation to customers, helping them secure funding during different stages of their development. Meanwhile, the Group will continue to raise its core competitiveness and advance its risk management mechanism and IT system, as well as to explore new and relatively low-cost financing channels so as to drive sustainable business growth in the most cost-effective manner.

About Sheng Ye Capital Limited (Stock code: 8469)
Sheng Ye Capital Limited is a specialised enterprise financial services provider offering accounts receivable financing and other related solutions mainly in the energy, construction and medical sectors in the PRC. It has a strong capital base with its principal operating subsidiary in the PRC having a registered capital of US$100 million. The Group was included as one of the constituents of MSCI China All Shares Small Cap Index in 2018. For more information about Sheng Ye Capital, please visit: http://www.shengyecapital.com/.

Media Enquiries
Strategic Financial Relations Limited
Iris Lee Tel: (852) 2864 4829 Email: iris.lee@sprg.com.hk
Katrina Leung Tel: (852) 2864 4857 Email: katrina.leung@sprg.com.hk
Queenie Chan Tel: (852) 2864 4851 Email: queenie.chan@sprg.com.hk
Fax: (852) 2527 1196

MIT’s research enterprise in Singapore launches new research group, boosting nation’s cell therapies R&D

MIT’s Research Enterprise in Singapore, SMART, launches a new research group, Critical Analytics for Manufacturing Personalized-Medicine (CAMP), as part of Singapore’s National Cell Manufacturing Initiative to overcome scientific and technical challenges in life-changing cell therapies.

— S$10 million a year to be invested in SMART CAMP in a multi-year effort
— New interdisciplinary research group, SMART CAMP, will bring together 35 MIT and Singapore investigators
— Complementary and integrated programme with Singapore’s Agency for Science Technology and Research (A*STAR) cell manufacturing effort, supported by the National Research Foundation (NRF) 
— SMART CAMP deploys MIT’s innovation methodologies in Singapore’s thriving biopharmaceutical industry, tapping market potential of billions a year.

SINGAPORE, July 15, 2019 – (Media OutReach) – Cell therapies, where cellular material is injected, grafted or implanted into a patient to treat a range of illnesses and medical conditions, are a vital and integral component of medicine today – promising treatment of tissue degenerative diseases, cancer, and autoimmune disorders.

However, significant challenges currently exist to prevent its widespread adoption including problems such as safety, potency, efficacy, and costs. To overcome these challenges, the Singapore-MIT Alliance for Research and Technology (SMART), together with A*STAR Institutes and supported by the National Research Foundation (NRF), has launched a new national initiative in Singapore that deploys MIT’s globally renowned applied innovation methodology combined with Singapore’s dynamic and growing biopharmaceutical manufacturing industry.

As part of the national initiative in cell manufacturing, CAMP is a new interdisciplinary research group within SMART that will focus on ways to produce living cells as medicine delivered to humans, leading to improved health outcomes. The National Research Foundation will support this multi-million, multi-year project that will bring together 35 MIT and Singapore investigators. They will be recruited from researchers working in SMART and Singapore institutes including A*STAR, KK Women’s and Children’s Hospital, the National University Hospital and local universities. Investigators from MIT in Cambridge, Massachusetts will also be recruited to support the programme.

“This is a field that is ripe for innovation, and one which we believe will benefit from both MIT’s and Singapore’s strengths,” said Eugene Fitzgerald, CEO and Director of SMART. “By applying our problem-solving research methodology, coupled with Singapore’s well-established biopharmaceutical manufacturing ecosystem, we are confident that we will be able to achieve market-ready breakthroughs.”

Since its inception in Singapore in 2007, SMART has pioneered innovations that have transformed and are transforming fields such as autonomous driving, agriculture, microelectronics, mechanics and microfluidics platforms for biology and medical diagnostics, and antimicrobial resistance.

SMART CAMP will be helmed by Professor Krystyn Van Vliet of MIT and Professor Hanry Yu of NUS and A*STAR. Professor Van Vliet is an engineer with expertise at the interface of materials, mechanics, and biological systems and is an experienced leader, currently serving as the Associate Provost and the Director of Manufacturing Innovation at MIT. Her current research stemming from earlier SMART collaborations is in clinical trials at the Singapore General Hospital, and the prior SMART team that she led has spun off several MedTech companies in Singapore.

Professor Van Vliet explained, “By addressing critical technology bottlenecks in how the next generation of personalised medicines is made, SMART CAMP researchers will help set the standards for innovating on quality by design. Imagine providing just the right living cells – the most sophisticated drug factories we know – to each patient, as quickly and safely as possible. Delivering on that promise requires exciting changes in the way we understand, engineer, measure, and select cells that offer a safe and effective medicine for that person’s ailment. And that goal, in turn, benefits from this investment in the research and researchers that can transform the manufacturing and analytics of biopharma products.”

Professor Yu is a physiologist with expertise interface between mechanobiology, biomaterials, imaging and AI-based data analytics. He is also a serial entrepreneur, recently forming six companies, and the founding member of the Mechanobiology Institute Research Centre of Excellence in Singapore. 

“This programme integrates experts from various disciplines, training staff and students who can think through the translational pipelines from basic knowledge and technology into commercially viable and clinically relevant solutions”, said Professor Yu. 

“There is a global need for safe and cost-effective cell therapies,” said Dr. Khiang Wee Lim, Executive Director of CREATE, NRF. “We believe that it is an area in which Singapore can provide innovation space and bring these transformational technologies to millions around the world. Advances in this area will also boost Singapore’s biopharmaceutical industry, bringing innovations and helping gain a lead in this promising market that is estimated to be worth billions.”

About Singapore-MIT Alliance for Research and Technology (SMART)

Singapore-MIT Alliance for Research and Technology (SMART) is MIT’s Research Enterprise in Singapore, established by the Massachusetts Institute of Technology (MIT) in partnership with the National Research Foundation of Singapore (NRF) since 2007. SMART is the first entity in the Campus for Research Excellence and Technological Enterprise (CREATE) developed by NRF. SMART serves as an intellectual and innovation hub for research interactions between MIT and Singapore. Cutting-edge research projects in areas of interest to both Singapore and MIT are undertaken at SMART. SMART currently comprises an Innovation Centre and six Interdisciplinary Research Groups (IRGs): Antimicrobial Resistance (AMR), BioSystems and Micromechanics (BioSyM), Critical Analytics for Manufacturing Personalized-Medicine (CAMP), Disruptive & Sustainable Technologies for Agricultural Precision (DiSTAP), Future Urban Mobility (FM) and Low Energy Electronic Systems (LEES). 

SMART research is funded by the National Research Foundation Singapore under the CREATE programme. For more information, please visit – http://smart.mit.edu

For media queries, please contact:
Andrew Wong 
SMART@bluetotem.co
+65 91993623